IGC

IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.

Wall Street analysts forecast IGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGC is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

IGC Pharma Inc revenue for the last quarter amounts to 191.00K USD, decreased -53.64 % YoY.

IGC Pharma Inc. EPS for the last quarter amounts to -0.02 USD, decreased -0.00 % YoY.

IGC Pharma Inc (IGC) has 70 emplpoyees as of December 15 2025.

Today IGC has the market capitalization of 32.29M USD.